ProteoThera

ProteoThera was a private early-stage biotechnology company focused on targeted drug delivery for musculoskeletal and autoinflammatory diseases. Its core technology was a proprietary matrix-binding (MB) fusion platform developed at Brigham and Women's Hospital and Harvard Medical School, designed to convert systemically delivered proteins, peptides, and small molecules into locally or subcutaneously retained therapeutics. The company's lead disclosed program, PRT-1000, was a matrix-binding interleukin 1 receptor antagonist intended for acute gout pain and related joint inflammation indications. ProteoThera also described broader applications in osteoarthritis, tissue regeneration, and other locally treated inflammatory conditions. Available sources suggest the company ultimately became inactive or out of business rather than advancing into later-stage clinical development.